What Shout does

TERIAK is a Tunisian pharmaceutical manufacturer founded in 1996 as a wholly-owned subsidiary of Groupe KILANI, a Tunisian conglomerate controlled by founders Lassaad and Rafik Kilani. The company operates four GMP- and WHO-compliant production sites: Jebel Ouest and El Fejja in Tunisia, Cinpharm in Cameroon (acquired 2015), and Cipharm in Côte d'Ivoire (majority stake acquired 2020). TERIAK's portfolio spans two business lines: (i) licensed contract manufacturing for multinational pharmaceutical companies — five of its license partners rank among the world's top eight pharmaceutical laboratories, including Sanofi, Novartis, GSK, Abbott, Ipsen, Servier, Grunenthal, Daiichi-Sankyo, and Biocodex — and (ii) proprietary branded generics across cardiology, infectious diseases, neurology-psychiatry, allergology, analgesics, pneumology, urology, and anticoagulation, marketed under brand names such as AMLODIS, TAVASTOR, LIPTA, AEROFOR, AERONIDE, DAPOX, and XABAN. Manufacturing capabilities cover tablets, coated tablets, capsules, dry syrups, suspensions, ointments, suppositories, sterile forms, DPI inhalation capsules, and large-volume solutions, with specialized beta-lactam lines at Cinpharm.

The go-to-market model is sales-led through an integrated group distribution apparatus: ARGANIA handles direct pharmacy distribution in Tunisia, KIPROPHA operates wholesale, PROCHIDIA serves hospitals, and MEDICIS runs medical promotion. Internationally, the company sells through external distributors and representation agencies across North Africa, Sub-Saharan Africa, and the Middle East, with Cipharm alone holding 359 marketing authorizations (AMM) active in 12+ African countries. Pricing is not publicly disclosed and operates through prescription-based distribution requiring professional medical advice. The company employs 722 collaborators and is led by CEO Sara Limam Masmoudi.

Name

Shout

Legal name

TERIAK

Website

https://teriak.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

501–1,000 employees

Short description

TERIAK is a Tunisian pharmaceutical manufacturer and subsidiary of Groupe KILANI, producing branded generics and licensed products for top global pharma companies across four GMP-compliant sites in Tunisia, Cameroon, and Côte d'Ivoire, serving African and Middle Eastern markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Pharmaceutical manufacturing
• Generic medications
• Licensed drug production
• GMP certified manufacturing
• Pharmaceutical distribution

Headquarters

HQ city

Carthage

HQ country

Tunisia

HQ region

Africa

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Licensed Pharmaceutical Manufacturing: Manufactures pharmaceutical products under license from multinational pharmaceutical companies. Five of TERIAK's license partners rank among the world's top eight pharmaceutical laboratories. Revenue generated through production fees and supply of licensed products.
2. Branded Generic Pharmaceuticals: Develops and sells proprietary generic pharmaceutical products under brand names. Products cover multiple therapeutic classes including cardiology, neurology, infectious diseases, and respiratory care.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels3 records

Core offering

TERIAK manufactures branded generic pharmaceutical products and produces drugs under license from multinational pharmaceutical companies. The portfolio spans cardiology, neurology, infectious diseases, psychiatry, allergology, analgesics, rheumatology, pneumology, and urology-nephrology therapeutic classes. Operations span four GMP-compliant production sites in Tunisia, Cameroon, and Côte d'Ivoire, supplying products to pharmacies, hospitals and wholesale distributors across Africa and the Middle East.

Product overview

TERIAK is a Tunisian pharmaceutical laboratory and subsidiary of Groupe KILANI. Founded in 1996, it is Tunisia's leading local pharmaceutical manufacturer with 722 collaborators across four production sites (Jebel Ouest, El Fejja in Tunisia, Cinpharm in Cameroon, and Cipharm in Côte d'Ivoire). The company manufactures generic pharmaceutical products under license for multinational pharmaceutical companies (five of which rank among the world's top eight) and has developed its own generic brand portfolio. TERIAK operates under GMP standards and serves markets across North Africa, Sub-Saharan Africa, and the Middle East. The product portfolio spans multiple therapeutic classes including cardiology-angiology (AMLODIS, TAVASTOR, LIPTA, COAPROZAR, CORAPRIL, APROZAR, APROFORT, NEBILUS, LOXEN LP, FLUDEX LP, DAFLON, RAPRIL, TAREG, COTAREG, VASTAREL), infectious diseases (ZELIVIR, TAVAFLOX, SIFLOKS, LAMISIL, AZRO), neurology-psychiatry (LYDOL, LEXOMIL, ESOPREX, RISPERIDONE TERIAK, MEMIXA, SERC, TANAKAN, VETIRA), allergology (XYLIX, CIPRACTINE, CLARIUS, ACTIFED RHUME), analgesics (TRAMAL, FORTALGIC, FORTADOL, Voltaren Retard), pneumology (AEROFOR, AERONIDE), urology-nephrology (TEROS, DAPOX), thrombolytics (XABAN), and supplements (TRYPTOMAG). The company also provides pharmacovigilance services and operates under strict quality policies (QSSSE).

Differentiator

Problem solved

Functional benefit

Products and services

• TERIAK Generic Pharmaceuticals Portfolio Manufactured and marketed by TERIAK across cardiology, infectious diseases, neurology, psychiatry, allergy, analgesics, rheumatology, pneumology and urology-nephrology therapeutic classes. Marketed under TERIAK brand names and distributed to pharmacies, wholesalers, and hospitals across Tunisia and Africa.
• Licensed Pharmaceutical Manufacturing Manufacturing services provided under license to multinational pharmaceutical companies. Production of branded products under license at the Jebel Ouest and El Fejja sites in Tunisia; supplies licensed products to multinational partners for local and regional markets.
• AMLODIS (Amlodipine) Generic medication containing Amlodipine (calcium channel blocker) used for treatment of hypertension and angina. For patients with cardiovascular conditions.
• TAVASTOR (Atorvastatin) Generic statin medication containing Atorvastatin for hypercholesterolemia reduction and cardiovascular event prevention. Available in 10mg, 20mg, 40mg, and 80mg dosages. For patients with elevated cholesterol or cardiovascular risk.
• LIPTA (Amlodipine+Atorvastatin) Fixed-dose combination of Amlodipine and Atorvastatin (10mg/10mg and 5mg/10mg dosages) for cardiovascular event prevention in hypertensive patients with multiple risk factors.
• COAPROZAR (Irbesartan+Hydrochlorothiazide) Fixed-dose combination of Irbesartan 300mg and Hydrochlorothiazide 25mg for essential hypertension when monotherapy is insufficient.
• CORAPRIL (Ramipril+Hydrochlorothiazide) Fixed-dose combination of Ramipril and Hydrochlorothiazide (10mg/25mg and 10mg/12.5mg dosages) for essential hypertension treatment.
• APROZAR (Irbesartan) Generic angiotensin receptor blocker containing Irbesartan 300mg for essential hypertension and diabetic nephropathy.
• APROFORT (Irbesartan+Amlodipine) Fixed-dose combination of Irbesartan 300mg and Amlodipine 10mg for essential hypertension when monotherapy is insufficient.
• NEBILUS (Nebivolol) Generic beta-blocker containing Nebivolol for essential hypertension and stable chronic heart failure in patients aged 70 and over.
• LOXEN LP (Nicardipine) Generic calcium channel blocker containing Nicardipine 50mg in extended-release capsules for hypertension treatment.
• FLUDEX LP (Indapamide) Generic diuretic containing Indapamide 1.5mg in extended-release tablets for essential hypertension.
• DAFLON (Diosmine+Hesperidine) Venotonic containing Diosmine and Hesperidine 500mg for treatment of venous insufficiency symptoms (heavy legs, pain) and hemorrhoidal crisis.
• RAPRIL (Ramipril) Generic ACE inhibitor containing Ramipril 10mg for hypertension, cardiovascular prevention, nephropathy treatment, and heart failure.
• COTAREG (Valsartan+Hydrochlorothiazide) Fixed-dose combination of Valsartan 160mg and Hydrochlorothiazide 25mg for essential hypertension when monotherapy is insufficient.
• XABAN (Rivaroxaban) Generic anticoagulant containing Rivaroxaban for stroke prevention in non-valvular atrial fibrillation and for DVT/PE treatment and recurrence prevention.
• VASTAREL (Trimetazidine) Generic antianginal medication containing Trimetazidine 35mg modified-release tablets for angina treatment in combination with other antianginal therapies.
• ZELIVIR (Valaciclovir) Generic antiviral containing Valaciclovir 500mg for Varicella-Zoster virus (shingles), Herpes simplex virus infections, and CMV prophylaxis after organ transplantation.
• TAVAFLOX (Levofloxacin) Generic fluoroquinolone antibiotic containing Levofloxacin for acute sinusitis, COPD exacerbations, community-acquired pneumonia, and anthrax treatment.
• LAMISIL (Terbinafine) Generic antifungal containing Terbinafine 250mg in B/28 packaging for onychomycosis and dermatophyte infections.
• AZRO (Azithromycin) Generic macrolide antibiotic containing Azithromycin for angina treatment, respiratory infections, and stomatological infections in children from 3 years.
• SIFLOKS (Ciprofloxacin) Generic fluoroquinolone antibiotic containing Ciprofloxacin 750mg for gonococcal urethritis, complicated UTIs, intestinal infections, and bone-joint infections.
• LYDOL (Pregabalin) Generic medication containing Pregabalin in capsules for neuropathic pain, epilepsy as adjunct therapy, and Generalized Anxiety Disorder.
• LEXOMIL (Bromazepam) Generic benzodiazepine containing Bromazepam 6mg for anxiety treatment and alcohol withdrawal prevention.
• ESOPREX (Escitalopram) Generic SSRI antidepressant containing Escitalopram 10mg/ml for major depressive episodes, panic disorder, social anxiety, GAD, and OCD treatment.
• RISPERIDONE TERIAK Generic atypical antipsychotic containing Risperidone 4mg for schizophrenia treatment, bipolar mania, and short-term treatment of persistent aggression in Alzheimer's and conduct disorder in children.
• MEMIXA (Memantine) Generic NMDA receptor antagonist containing Memantine 20mg for moderate to severe Alzheimer's disease treatment.
• SERC (Betahistine) Generic medication containing Betahistine 8mg for symptomatic treatment of recurrent vertigo with or without cochlear signs.
• TANAKAN (Ginkgo Biloba) Generic phytopharmaceutical containing Ginkgo Biloba 40mg in coated tablet form for symptomatic treatment of chronic cognitive deficit in elderly, intermittent claudication, visual acuity disorders, and tinnitus.
• VETIRA (Levetiracetam) Generic anticonvulsant containing Levetiracetam for monotherapy in newly diagnosed epilepsy and as adjunct therapy for partial seizures, juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures.
• XYLIX (Levocetirizine) Generic antihistamine oral drops containing Levocetirizine 5mg/ml for symptomatic treatment of allergic rhinitis and idiopathic urticaria.
• CIPRACTINE (Cyproheptadine) Generic antihistamine and appetite stimulant containing Cyproheptadine for symptomatic treatment of chronic/acute allergic manifestations and appetite stimulation in patients with weight loss.
• CLARIUS (Desloratadine) Generic antihistamine oral solution containing Desloratadine 0.5mg/ml for allergic rhinitis and urticaria in adults, adolescents, and children over 1 year.
• TRYPTOMAG (Magnesium supplement) Dietary supplement product containing Magnesium as a nutritional supplement.
• TRAMAL RETARD (Tramadol) Generic opioid analgesic containing Tramadol 100mg in extended-release form for moderate to severe pain treatment.
• FORTALGIC (Paracetamol+Codeine) Fixed-dose combination analgesic containing Paracetamol 300mg and Codeine 25mg for moderate to severe pain not responding to peripheral analgesics alone.
• FORTADOL (Paracetamol+Tramadol) Fixed-dose combination analgesic containing Paracetamol 37.5mg and Tramadol 325mg for pain treatment.
• Voltareene Retard (Diclofenac) Generic NSAID containing Diclofenac for anti-inflammatory and analgesic purposes.
• AEROFOR (Formoterol) Long-acting bronchodilator containing Formoterol for treatment of respiratory conditions such as asthma and COPD.
• AERONIDE (Budesonide) Inhaled corticosteroid containing Budesonide for treatment of respiratory conditions such as asthma and COPD.
• TEROS (Tadalafil) Generic PDE5 inhibitor containing Tadalafil for treatment of erectile dysfunction and benign prostatic hyperplasia symptoms in adult men.
• DAPOX (Dapoxetine) Generic SSRI containing Dapoxetine 60mg for premature ejaculation treatment in adult men aged 18-64.
• ACTIFED RHUME (Pseudoephedrine+Triprolidine) Cold medication combining Pseudoephedrine and Triprolidine for relief of cold symptoms.
• SITA Pharmaceutical Product New pharmaceutical product launch by TERIAK; specific therapeutic indication and formulation details were not disclosed in source data.
• Pharmacovigilance Services Drug safety monitoring services operated by TERIAK and MEDICIS to track, report, and manage adverse drug reactions across the company's product portfolio in compliance with pharmaceutical regulatory requirements.
• CINPHARM Manufacturing Services (Cameroon) Pharmaceutical manufacturing services at the Cinpharm Douala (Cameroon) site, featuring three units: General Formulation, Beta-lactam antibiotics, and Massive Solutions. Operates in compliance with BPF and WHO standards. Acquired by Groupe Kilani in 2015.
• CIPHARM Manufacturing Services (Côte d'Ivoire) Pharmaceutical manufacturing services at the Cipharm Abidjan (Côte d'Ivoire) site producing capsules, tablets, and syrups. Compliant with BPF and WHO standards. Operational in 12+ African countries with 359 registered marketing authorizations. Majority stake acquired by Groupe Kilani in 2020.

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core.

• SanoficoreOEM/ Whitelabel/ Licensing PartnerGlobal pharmaceutical company licensing manufacturing rights to TERIAK for various pharmaceutical products. Sanofi is among the world's leading pharmaceutical companies.
• NovartiscoreOEM/ Whitelabel/ Licensing PartnerMajor multinational pharmaceutical corporation providing license partnerships to TERIAK for pharmaceutical manufacturing.
• GSK (GlaxoSmithKline)coreOEM/ Whitelabel/ Licensing PartnerGlobal healthcare company engaged in license partnerships with TERIAK for pharmaceutical production.
• AbbottcoreOEM/ Whitelabel/ Licensing PartnerDiversified healthcare company maintaining licensing arrangements with TERIAK for pharmaceutical manufacturing.
• IpsencoreOEM/ Whitelabel/ Licensing PartnerFrench biopharmaceutical company providing license partnerships to TERIAK for specialty pharmaceutical products.
• ServiercoreOEM/ Whitelabel/ Licensing PartnerIndependent international pharmaceutical company engaged in licensing partnerships with TERIAK.
• GrunenthalcoreOEM/ Whitelabel/ Licensing PartnerPharmaceutical company specializing in pain management providing license partnerships to TERIAK.
• FrilabcoreOEM/ Whitelabel/ Licensing PartnerSwiss pharmaceutical laboratory providing licensing partnerships for TERIAK operations.
• Daiichi-SankyocoreOEM/ Whitelabel/ Licensing PartnerJapanese global pharmaceutical company engaged in licensing arrangements with TERIAK.
• AbdiibrahimcoreOEM/ Whitelabel/ Licensing PartnerTurkish pharmaceutical company providing licensing partnerships to TERIAK for regional pharmaceutical production.
• BiocodexcoreOEM/ Whitelabel/ Licensing PartnerFrench pharmaceutical company providing license partnerships to TERIAK for specialty products including probiotics and neurological treatments.
• Laboratoire XOcoreOEM/ Whitelabel/ Licensing PartnerFrench pharmaceutical laboratory providing licensing partnerships to TERIAK.
• Groupe KilanicoreStrategic or Co-development PartnerParent company controlling TERIAK. Founded in 1986, Groupe Kilani is a major player in health, beauty, and marketing in Tunisia. Majority controlled by founders Lassaad and Rafik Kilani. TERIAK is a subsidiary developing synergies with other Group companies for distribution and medical promotion.
• CINPHARM (Cameroon)coreStrategic or Co-development PartnerTERIAK acquired Cinpharm from Groupe Kilani in 2015. Cinpharm is the first laboratory in Cameroon fully compliant with international standards, featuring three distinct manufacturing units: General Formulation, Beta-lactam antibiotics, and Massive Solutions. Strategic platform for Sub-Saharan African market access.
• CIPHARM (Côte d'Ivoire)coreStrategic or Co-development PartnerGroupe Kilani acquired majority stake in Cipharm in 2020 in Côte d'Ivoire. Cipharm operates in 12+ African countries with 359 registered marketing authorizations. Manufacturing capsules, tablets, and syrups compliant with BPF pharmaceutical standards and WHO guidelines.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Julphar (Gulf Pharmaceutical Industries): One of the largest pharmaceutical manufacturers in the Middle East, producing generics across multiple dosage forms including sterile injectables. Comparable to TERIAK in mid-sized regional generics manufacturing with multi-site GMP operations and similar therapeutic-category breadth.
• EIPICO (Egyptian International Pharmaceutical Industries Company): One of the largest Egyptian pharma manufacturers producing a broad portfolio of generic medicines across multiple therapeutic classes with significant MENA and Africa distribution. Comparable in product breadth, regional positioning and generics manufacturing model.
• Eva Pharma: Major Egyptian pharmaceutical manufacturer producing branded generics across multiple therapeutic classes with GMP-certified production and Africa/MENA exports. Comparable to TERIAK as an Africa-and-MENA-focused generics manufacturer of similar scale with licensing and export orientations.
• Strides Pharma Science: Indian generics manufacturer with strong presence in Africa (Strides Global) producing multiple dosage forms including sterile products under license for multinationals. Comparable to TERIAK in licensing-based model, Africa distribution and multi-form manufacturing capabilities.
• Aspen Pharmacare Holdings: Largest pharmaceutical manufacturer in Africa, operating multiple GMP-compliant production sites and supplying branded and generic medicines across the continent. Most directly comparable to TERIAK as a multi-site African generics manufacturer with international licensing partnerships.
• Adcock Ingram Holdings: South African pharmaceutical manufacturer producing generics, OTC and prescription medicines across multiple therapeutic categories with its own distribution. Comparable to TERIAK in therapeutic breadth, multi-dosage manufacturing and Africa-centric distribution.
• Spimaco (Saudi Pharmaceutical Industries & Medical Appliances Corporation): Leading Saudi pharmaceutical manufacturer with GMP-certified facilities producing generics and licensing products for multinational partners across MENA. Comparable in licensing-driven, multi-therapeutic generics manufacturing with regional distribution.
• Cipla (including Cipla Africa): Major Indian generics manufacturer with a significant and explicit Africa franchise, multi-form manufacturing and long-standing licensing relationships with multinational innovators. Highly comparable to TERIAK in business model (licensing + branded generics) and Africa focus.

Broad incumbents

• Novartis: Global pharmaceutical major and one of TERIAK's core license partners. Included as a broad incumbent because Novartis licensing terms — alongside Sanofi and GSK — are key determinants of TERIAK's contract manufacturing volumes and product mix.
• Sanofi: One of TERIAK's principal license partners and a top global pharmaceutical company with broad innovative and generics franchises. Included as a broad incumbent relevant because licensing economics with Sanofi materially shape TERIAK's production volumes.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/teriaklaboratoires
• LinkedInlinkedin.com/company/laboratoires-teriak

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Shout